MicroRNAs (miRs) are a novel class of cellular bioactive molecules with critical functions in the regulation of gene expression in normal biology and disease. MiRs are frequently misexpressed in cancer, with potent biological consequences. However, relatively little is known about miRs in pediatric cancers, including sarcomas. Moreover, the mechanisms behind aberrant miR expression in cancer are poorly understood. Ewing sarcoma is an aggressive pediatric malignancy driven by EWS/Ets fusion oncoproteins, which are gain-of-function transcriptional regulators. We employed stable silencing of EWS/Fli1, the most common of the oncogenic fusions, and global miR profiling to identify EWS/Fli1-regulated miRs with oncogenesis-modifying roles in Ewing sarcoma. In this report, we characterize a group of miRs (100, 125b, 22, 221/222, 27a and 29a) strongly repressed by EWS/Fli1. Strikingly, all of these miRs have predicted targets in the insulin-like growth factor (IGF) signaling pathway, a pivotal driver of Ewing sarcoma oncogenesis. We demonstrate that miRs in this group negatively regulate the expression of multiple pro-oncogenic components of the IGF pathway, namely IGF-1, IGF-1 receptor, mammalian/mechanistic target of rapamycin and ribosomal protein S6 kinase A1. Consistent with tumorsuppressive functions, these miRs manifest growth inhibitory properties in Ewing sarcoma cells. Our studies thus uncover a novel oncogenic mechanism in Ewing sarcoma, involving post-transcriptional derepression of IGF signaling by the EWS/Fli1 fusion oncoprotein via miRs. This novel pathway may be amenable to innovative therapeutic targeting in Ewing sarcoma and other malignancies with activated IGF signaling.
IGF
Ewing sarcoma, the second most common cancer of bone and soft tissue in adolescents and young adults, is an aggressive malignancy with poor long-term outcome (Ludwig, 2008) . The pathogenesis of Ewing sarcoma is driven by EWS/Ets fusion oncoproteins, which are absolutely necessary and, in the appropriate context, may be sufficient for tumorigenesis (Arvand and Denny, 2001; Janknecht, 2005; Riggi and Stamenkovic, 2007; Jedlicka, 2010) . Ets fusion oncoproteins, of which EWS/Fli1 is the most common, are highly expressed, gain-of-function regulators of gene expression that activate an oncogenic program in the cell of origin of the tumor, likely a mesenchymal progenitor cell (Riggi et al., 2005; Tirode et al., 2007) . EWS/Ets fusions function as transcriptional regulators, with the Ets DNA-binding domain providing target specificity (Riggi and Stamenkovic, 2007; Jedlicka, 2010) . Activation of downstream gene expression is achieved via a potent transcription activation domain within the EWS component of the fusion (Riggi and Stamenkovic, 2007) . Interestingly, EWS/Ets silencing and rescue experiments identify more downregulated than upregulated target genes by EWS/Ets (Prieur et al., 2004; Smith et al., 2006) . Mechanisms of transcriptional repression in Ewing sarcoma include both EWS/Ets fusions themselves (Im et al., 2000; Yang et al., 2010) , and downstream transcriptional regulators such as Nkx2.2, NR0B1 and EZH2 (Kinsey et al., 2006; Smith et al., 2006; Richter et al., 2009) . Another possible, but currently unexplored, mechanism of target gene regulation by EWS/Fli1 is microRNAs (miRs).
A number of growth factor pathways are active in Ewing sarcoma, with the insulin-like growth factor (IGF) signaling pathway being of paramount importance (Kim et al., 2009a; Jedlicka, 2010) . IGF-1 is a target of EWS/Ets oncoproteins and acts, via an autocrine loop, on the IGF-1 receptor (IGF-1R; Yee et al., 1990; Scotlandi et al., 1996; Cironi et al., 2008; Herrero-Martin et al., 2009) . EWS/Ets fusions also downregulate expression of IGF-binding proteins (Prieur et al., 2004) , thus further enhancing the activity of this autocrine loop. Ewing sarcomas consistently express IGF-1R and exhibit activation of downstream mitogen-activated protein kinase and phosphatidyl inositol 3 kinase pathways (Scotlandi et al., 1996; Toretsky et al., 1999; Silvany et al., 2000; Benini et al., 2004) . Monoclonal antibody and small molecule inhibitors of IGF-1R impair Ewing sarcoma cell and tumor growth (Scotlandi et al., 2005; Martins et al., 2006; Manara et al., 2007) , and are currently in clinical trials as the chief adjunctive biological therapy for this aggressive cancer (Ludwig, 2008) . Although clearly important, little is known at present about the details of the IGF signaling pathway in Ewing sarcoma, including levels, regulation and mutational status of critical signaling components. MiRs are important regulators of growth factor signaling (Inui et al., 2010) , but their role in IGF pathway control is at present largely uncharacterized.
MiRs represent a novel class of cellular bioactive molecules with critical functions in the regulation of gene expression in normal biology and disease (Ghildiyal and Zamore, 2009) . MiRs are short (20-30 nucleotide) RNA molecules that bind to protein-coding messenger RNA (mRNA) molecules, predominantly in the 3 0 untranslated region (UTR; Ghildiyal and Zamore, 2009 ). This binding results in decreased synthesis of the coded protein, by a number of mechanisms including increased mRNA degradation and inhibition of translation (Ghildiyal and Zamore, 2009 ). In cancer, miRs have been shown to function as potent tumor suppressors or oncogenes (Sotiropoulou et al., 2009; Visone and Croce, 2009 ). Importantly, miRs represent potentially powerful therapeutic agents and/or targets, a concept now borne out in a number of preclinical studies (Weidhaas et al., 2007; Trang et al., 2008; Wang and Wu, 2009 ). At present, very little is known about miRs in pediatric cancers and sarcomas. Further, despite their importance, little is currently known about the regulation of miR expression in normal physiology and disease. Ets transcription factors, which provide the DNA-binding component in Ewing sarcoma oncogenic fusions, have been shown to regulate miR expression (Fukao et al., 2007; Fujita et al., 2008; Cowden Dahl et al., 2009) .
We hypothesized that regulation of miR expression by EWS/Ets fusions represents an important mechanism controlling oncogenesis in Ewing sarcoma. In order to identify candidate miRs involved in EWS/Ets-mediated oncogenesis, we employed an EWS/Fli1 stable silencing system in Ewing sarcoma cells, as such systems are well established and currently represent the optimal cellular context for the study of Ewing sarcoma biology (Kinsey et al., 2006; Smith et al., 2006) . Similar to the approach of others , we employed shRNAs targeted to the 3 0 end of Fli1 to target the EWS-Fli1 fusion (the unrearranged Fli1 gene is not expressed in Ewing sarcoma), using a lentiviral delivery system. As shown in Figure 1a , we achieved potent knockdown of EWS/Fli1 using two such shRNAs (EFsh1 and EFsh1), compared with the off-target control (shRNA to EGFP). Importantly, this knockdown was sufficient to downregulate the expression of two established EWSFli1 target genes, Nkx2.2 and NR0B1 (Kinsey et al., 2006; Smith et al., 2006; Figure 1b) . To further ensure the specificity of EWS/Fli1 silencing, we additionally adapted a published retroviral stable knockdown system, which employs a different 3 0 Fli1-targeting shRNA (EF2) and a different control shRNA (luciferase; Smith et al., 2006) . This system effected robust EWS/Fli1 silencing of similar potency to our lentiviral system ( Figure 1c) . Thus, we achieved stable and specific knockdown of the EWS-Fli1 oncoprotein in Ewing sarcoma cells.
In order to identify EWS/Fli1-regulated miRs, we performed miR microarray screening for miRs differentially expressed between A673 Ewing sarcoma cells with stably silenced EWS/Fli1 and control. From miRs differentially expressed by array, we initially chose to focus on EWS/Fli1-repressed miRs (that is, those upregulated upon EWS/Fli1 silencing), as these represented candidate tumor suppressors and thus novel antitumor agents in Ewing sarcoma. Of the 30 miRs upregulated upon EWS/Fli1 knockdown with a false discovery rate p0.01, we further focused on those showing the greatest change (at least 1.5-fold by array). As individual miRs have many mRNA targets (Bartel, 2009; Ghildiyal and Zamore, 2009 ), we next queried whether any of these miRs shared common target pathways, using the DIANA-mirPath algorithm and Target Scan 5 (http://diana.cslab.ece.ntua.gr). Strikingly, 7 of the 13 miRs most highly changed by the above criteria showed predicted pro-oncogenic targets in the IGF-1 signaling pathway, including IGF-1 itself and its receptor, IGF-1R. Given the importance of this pathway in Ewing sarcoma oncogenesis, these miRs, namely miRs 22, 100, 125b, 221, 222, 27a and 29a, were selected for further analysis as potential mediators of EWS/Fli1 oncogenesis through the IGF pathway ( Figure 1d) . First, to verify the array results, we quantified relative expression levels of the miRs using qRT-PCR in all stable knockdown cell lines (EFsh1, EFsh2 and EF2) and controls (EGFP and luc). All EWS/Fli1-targeted shRNAs showed increased levels of these miRs relative to matched off-target controls (Figure 1d ), confirming that the changes observed were specific to EWS/Fli1 silencing. We next asked whether the miRs are expressed at lower levels in Ewing sarcoma cell lines compared with human mesenchymal progenitor cells, the putative cell of Ewing sarcoma origin (Riggi and Stamenkovic, 2007) , as would be expected of tumor suppressors. As shown in Figure 1e , all of the miRs showed lower expression in a panel of five Ewing sarcoma cell lines, compared with two different human mesenchymal progenitor cell lines, supporting a candidate tumorsuppressive role. Interestingly, the differences between Ewing sarcoma cell lines and human mesenchymal progenitor cells were even greater than those due to EWS/Fli1 silencing, presumably in part reflecting the absence, rather than the reduction in levels, of EWS/Fli1.
The control of miR levels in the cell has both a transcriptional component and post-transcriptional processing components, all of which are subject to regulation (Davis and Hata, 2009; Kim et al., 2009b; Winter et al., 2009) . As EWS/Fli1 is a transcriptional regulator, we hypothesized that the observed changes in the levels of the mature miRs upon EWS/Fli1 silencing could be because of regulation at the level of the miR primary transcript. As shown in Figure 2a , this ; the off-target control shRNA to EGFP has been described (Porter and DeGregori, 2008) . Replication-incompetent infectious virus was prepared by transient transfection of 293FT cells, using the ExGen500 reagent (Fermentas, Glen Burnie, MD, USA), with shRNA construct, and packaging constructs expressing VSV-G, Gag, Pol, and Rev (Porter and DeGregori, 2008) per standard protocols (Invitrogen, Carlsbad, CA, USA). A673 cells were infected with similar titers of virus and selected with puromycin (3 mg/ml). Following 10 days of culture, cell pools were harvested for protein and RNA, with all groups at similar confluence (50-70%) at the time of harvest. Total cellular RNA was isolated using the TRIzol reagent (Invitrogen), per manufacturer instructions. Protein extract preparation, SDS-PAGE, immunoblotting and enhanced chemiluminescence detection were performed essentially as described previously (Jedlicka et al., 2009) . EWS/Fli1 protein levels were determined by immunoblotting with Fli1 antibody (BD Biosciences, San Jose, CA, USA; 554266) and tubulin (Calbiochem, La Jolla, CA, USA; CP06) as loading control. The numerical values represent the EWS/Fli1 to tubulin ratio as determined by densitometric quantitation, with the value in the control set to 1. (b) The expression of two established EWS/Fli1 targets (Nkx2.2 and NR0B1) was determined by qRT-PCR (normalized to actin); results represent mean and standard deviation of qRT-PCR performed on RNAs from triplicate cell culture plates. (c) The 'EF2' and 'luc' off-target control shRNA constructs were generated in pSUPERRetro-Puro (Oligoengine, Seattle, WA, USA) using standard cloning techniques, and sequence-verified. Preparation of virus and infection of A673 cells were as in a, except that the packaging construct pCL-Ampho (Naviaux et al., 1996) was used. EWS/Fli1 expression levels were determined as in a. (d) Global miR expression profiling was performed on triplicate RNA samples from cells stably expressing EFsh1 and shEGFP, by Dharmacon/Thermo Fisher Scientific (Lafayette, CO, USA), using an Agilent-type custom array containing miRs in the Sanger 10.1 database. Relative intensity data for six experiments were subjected to statistical filtering, keeping miR probes called 'present' with P-value p0.05 in at least three of the six experiments. The resulting data were inter-array scaled, and differential expression analysis was performed using textbook analysis of variance with FDR (false discovery rate) multiple test correction. A list of miR probes significantly different (FDR p0.01) between the two treatment groups is shown in Supplement Figure S1 . The table shows miRs selected for further study, as described in the text. (e) Changes in miR levels observed by microarray were verified by qRT-PCR, using the miScript SYBRgreen qRT-PCR system (Qiagen, Valencia, CA, USA) with U6 RNA as the endogenous control. Results are expressed as mean and standard deviation of fold miR increase relative to matched control (shEGFP for shEF1 and shEF2, and luc for EF2; *, not done). (f) RNA was isolated from triplicate culture plates of five different Ewing sarcoma cell lines (A673, SK-N-MC, SK-ES-1, EWS502 and TC71), and low-passage human mesenchymal progenitor cells (hMPC) from two different sources (ScienCell (SC) and Lonza (L)). All cell lines were grown in Dulbecco's modied Eagle's medium supplemented with 10% fetal calf serum, under standard tissue culture conditions (miR expression levels in the hMPCs were similar when the cells were grown in proprietary progenitor cell media and DMEM/10% fetal calf serum). MiR levels were determined by qRT-PCR, normalized to U6 RNA. The average normalized value in A673 cells was set to 1. Results are expressed as mean and standard deviation. (a) Pri-miR levels were determined by qRT-PCR, with U6 RNA as the endogenous control, using primers outside the pre-miR hairpin sequence, but within the known/predicted primary transcript. The ratio of expression in A673 cells with stably silenced EWS/Fli1 (EFsh1) to control (shEGFP) is shown (error bars represent standard deviation). (b) The type 1 EWS/Fli1 oncogenic fusion was RT-PCR cloned from SK-N-MC Ewing sarcoma cells into the pCMV6 expression vector (Origene), and subsequently subcloned (along with the C-terminal Myc/DDK epitope tag) into the pCDH-CMV-MCS-EF1-Puro expression vector (System Biosciences, Mountain View, CA, USA); all products were sequence-verified. Infectious lentivirus, prepared for the pCDH-EWS/Fli1 expression construct and control (empty vector) as in Figure 1a above, was used to infect 293FT cells. Following selection with puromycin (2 mg/ml), protein extract preparation and EWS/Fli1 immunoblotting were performed as in Figure 1a to confirm expression of a protein product of the predicted size. (c, d) Quantification of miR primary transcript (pri-miR) and miR levels in RNA isolated from EWS/Fli1-expressing 293FT cells and controls was performed as in Figure  1e and 2a. Results are plotted as mean and standard deviation of two independent experiments, each performed in triplicate (except for the pri-miR-27a data, which represent one experiment performed in triplicate). (e) Candidate EWS/Fli1 DNA-binding sites in the miR promoters were identified by searching predicted miR promoter sequence (roughly À2 kb to þ 0.5 kb relative to the transcription start site; Ozsolak et al., 2008; Corcoran et al., 2009; Eyholzer et al., 2010) ) with the Fli1 position weight matrix (Wei et al., 2010) , using the ConSite transcription factor binding site prediction algorithm (http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite). Note that miRs 221 and 222 share a common promoter, while the miR-125b promoter has not been defined and may be shared with miR-100, as in lower organisms (Sokol et al., 2008) . (f) Chromatin immunoprecipitation (ChIP) analysis of EWS/Fli1 binding to the miR-100 promoter. A673 cells (9 Â 10 7 ) were collected by centrifugation and resuspended in medium containing 1% formaldehyde for crosslinking. Following rocking at room temperature for 10 min, crosslinking was terminated by the addition of 0.125 M glycine and rocking for an additional 5 min. ChIP was then performed using antibody to Fli1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc-356-X) or IgG (Cell Signaling, Danvers, MA, USA, 2729S) as control, as described (Schmidt et al., 2008) , except that sonication was done at 25% power, 25 cycles, 15 s on, 1 min off. The negative control (Neg) is an average of the ChIP fold-enrichment at the Albumin and Bcl promoters, subsequently set to 1; ChIP of the NR0B1 promoter is the positive control (Gangwal et al., 2008) . The positions of the qPCR amplicons (B250-400 bp each) relative to the miR-100 transcription start site are indicated. Results are represented as mean and standard error of the mean of two independent ChIP experiments, each performed in duplicate.
hypothesis was supported by measurement of miR primary transcript levels, all of which were increased in A673 cells with stably silenced EWS/Fli1 compared with controls. To test this hypothesis further, we ectopically expressed EWS/Fli1 in 293FT cells, which do not harbor EWS/Fli1, but tolerate its expression ( Figure 2b ). As shown in Figures 2c and d , EWS/Fli1 expression resulted in downregulation of both the primary transcript and the mature form, respectively, of miRs 100, 125b, 22, 221 and 27a. These data support transcriptional repression as the mechanism responsible for the downregulation of these miRs by EWS/Fli1. The lack of regulation of miR-29a by EWS/Fli1 in 293 cells may reflect the absence of a required cofactor, or downstream mediator. Target repression by EWS/Fli1 in Ewing sarcoma can occur by direct or indirect mechanisms (Jedlicka, 2010) . To determine whether a direct mechanism is involved, we searched for candidate EWS/Fli1 DNA-binding sites in the miR promoter regions and were able to identify at least one site in each (Figure 2e ). We further assayed for EWS/Fli1 binding to the promoter of miR-100, the most regulated miR, using chromatin immunoprecipitation. As shown in Figure 2f , compared with negative (Neg) and positive (NR0B1) controls, we observed enrichment of EWS/Fli1 binding to the more proximal upstream (amplicons -1324 and -510) and immediate downstream (amplicon þ 510) regions of the miR-100 promoter. As these regions contain the candidate EWS/Fli1 sites (À660 and þ 120; Figure 2e ), this finding suggests that miR-100 downregulation may involve direct transcriptional repression by EWS/Fli1. The modest degree of enrichment, however, suggests that other, indirect, mechanisms may also have a role. Taken together, these data indicate that miR downregulation by EWS/Fli1 in Ewing sarcoma involves transcriptional repression, and that, for at least some miRs, this may involve direct repression by EWS/Fli1 itself.
We next examined the effects of the miRs on regulation of their predicted targets in the IGF signaling pathway. Activation of the IGF signaling pathway in Ewing sarcoma has an important autocrine component. Indeed, expression of IGF-1 itself is positively regulated by the EWS/Fli1 oncoprotein (Riggi et al., 2005; Cironi et al., 2008; Herrero-Martin et al., 2009) . Strikingly, four of the miRs, namely miRs 27a, 29a and 221/222, were predicted to target the IGF-1 3 0 UTR. We thus tested whether overexpression of these miRs has an effect on IGF-1 expression. As shown in Figure 3a , overexpression miR-27a resulted in a robust (B30%) decrease in IGF-1 production per cell. Overexpression of miRs 29a and 221 did not lead to similar changes (data not shown). Thus, miR-27a negatively regulates IGF-1 expression in Ewing sarcoma. Target prediction algorithms also identified the IGF-1R as a candidate target of miRs 100 and 22. As shown in Figure 3b , miR-100 overexpression in A673 cells resulted in a decrease in the IGF-1R protein level, as determined by immunoblotting, compared with control. Overexpression of miR-22 did not affect IGF-1R protein levels (data not shown). MiR-100 has previously also been shown to target mTOR (mammalian/mechanistic target of rapamycin), a downstream mediator of IGF signaling with pro-oncogenic functions (Ciuffreda et al., 2010) , in other systems (Wang et al., 2008a; Nagaraja et al., 2010) . We thus quantified mTOR levels in the same miR-100 overexpression experiments, and were able to verify downregulation in A673 cells (Figure 3c ). Target prediction algorithms also identified RSK1 (ribosomal protein S6 kinase A1), a substrate of Erk in the mitogenactivated protein kinase arm of the IGF signaling pathway with pro-oncogenic functions (Carriere et al., 2008) , as a candidate target for miR-125b. As shown in Figure 3d , overexpression of miR-125b in A673 cells resulted in a downregulation of RSK1 protein levels. In order to verify that regulation of the above targets was through a direct mechanism, we tested miR regulation of the predicted 3 0 UTR sites (Figure 3e ) using the siCHECK dual luciferase reporter system. Two previous studies have demonstrated direct regulation of the mTOR 3 0 UTR by miR-100 (Wang et al., 2008a; Nagaraja et al., 2010); we thus focused our studies on the novel miR-target pairs. As shown in Figure 3f , compared with negative control, miR-100 robustly inhibited reporter expression through its predicted site in the IGF-1R 3 0 UTR, but had no effect when the miR seed sequence was mutated. Similarly, miR-125b specifically inhibited reporter activity through its predicted site in the RSK1 3 0 UTR (Figure 3f) . Surprisingly, we were unable to demonstrate direct regulation of the IGF-1 3 0 UTR by miR-27a (Figure 3f ), suggesting that the regulation of IGF-1 protein levels occurs via other mechanisms. Thus, a number of the EWS/Fli1-repressed miRs converge on pro-oncogenic targets in the IGF signaling pathway, with at least some exerting their effects directly through 3 0 UTR interactions. The IGF signaling pathway has a critical prooncogenic role in Ewing sarcoma, including regulation of cell growth (Yee et al., 1990; Scotlandi et al., 1996) . We therefore overexpressed each of the EF-repressed miRs in A673 Ewing sarcoma cells, and determined effects on cell growth. MiR overexpression was achieved by transient transfection of miR mimics, which we found to be the most effective means to approximate miR expression differences between Ewing sarcoma cell lines and MPCs (Figure 2b ; up to 30-76-fold difference). As shown in Figure 4a , overexpression of each miR resulted in inhibition of cell growth, with miRs 22, 125b and 221 showing the strongest effect. MiR overexpression levels in these experiments are shown in Figure 4b . In order to further probe the function of miR-100, the most strongly EWS/Fli1-regulated miR in the group (Figure 2a) , we generated A673 cells stably overexpressing miR-100 using a lentiviral delivery system of a miR-100 precursor. Using this system, we were able to achieve B6-7-fold overexpression (Figure 4c) , which was less than the difference between Ewing sarcoma cell lines and MPCs, as well as A673 cells with strong EWS/Fli1 knockdown and controls. Strikingly, even at such modest overexpression levels, miR-100 robustly inhibited anchorage-independent cell growth, as assayed by colony formation in soft agar, by B35% (Figures 4d and e) . Taken together, our findings support tumor-suppressive functions for miRs 22, 100, 125b, 221, 27a and 29a in Ewing sarcoma, in part through negative regulation of pro-oncogenic components of the IGF-1 signaling pathway.
We further examined published data on EWS/Fli1-regulated genes for possible additional relevant targets of these miRs. Kinsey et al. (2006) identified a group of 34 genes upregulated by EWS/Fli1 in three different Ewing sarcoma cell lines. When these were subjected to a miR target prediction algorithm (TargetScan), nine of the genes emerged as candidate targets of miRs 22, 100, 125b, 221/222, 27a and 29a (Supplementary Table S1 ). Moreover, six of the genes were predicted to be targeted by a single member of this group, miR-125b. One of these target genes, GSTM4, has been demonstrated to have a pro-oncogenic function downstream of EWS/ Fli1 in Ewing sarcoma (Luo et al., 2009) . Thus, miR repression may represent one mechanism of induction of these target genes by EWS/Fli1. Moreover, repression of these EWS/Fli1 targets may represent an additional mechanism by which these miRs exert tumor-suppressive effects.
The IGF signaling pathway has a central role in Ewing sarcoma oncogenesis, as well as a variety of other cancers, including other pediatric solid tumors (Kim et al., 2009a; Jedlicka, 2010) . Key components of the pathway, namely IGF-1 (Cironi et al., 2008) and IGFBP3 (Prieur et al., 2004) , have previously been shown to be targeted directly by the transcriptional activity of EWS/Fli1. Our studies uncover a novel mechanism whereby EWS/Fli1 regulates the expression of pro-oncogenic IGF signaling pathway components indirectly via miRs (Supplementary Figure S2) . MiRs have recently been identified as important regulators of signaling pathway activity in other systems (Inui et al., 2010) . To our knowledge, our findings of a pivotal fusion oncoprotein regulating multiple miRs, which Figure 3 Inhibition of expression of IGF pathway targets by EWS/Fli1-repressed miRs. (a) A673 cells were transiently transfected with negative control mimic or miR-27a mimic (20 nM; Applied Biosystems, Carlsbad, CA, USA), using the Lipofectamine 2000 reagent, and cultured in growth medium with 10% serum. The medium was changed 2 days after transfection, and IGF-1 levels in the medium were quantified by ELISA (R&D Systems, Minneapolis, MN, USA) per manufacturer protocol an additional 2 days later. To determine IGF production per cell, IGF-1 levels in growth medium alone were subtracted, and the resulting value was normalized to cell number. Results are expressed as mean and standard error of the mean of three independent experiments; P ¼ 0.0002. (b, c) A673 cells were infected with control or pCDH-miR-100-Puro lentivirus, using the same methods as in Figure 1a . The pCDH-miR-100-Puro construct was generated by subcloning miR-100 precursor sequence from the pCDH-miR-100-GFP construct into the pCDH-Puro construct (both from System Biosciences), using standard techniques. Following puromycin selection (2 mg/ml), IGF-1R and mTOR expression levels were determined by western blotting of whole-cell extracts with specific antibodies (Cell Signaling; 3027 and 2972, respectively), and tubulin as loading control. Figures to the right of the immunoblots show quantification of expression levels by densitometric scanning; data are represented as mean and standard deviation of at least two independent experiments. (d) A673 cells were transiently transfected with negative control or miR-125b mimic as in a. RSK1 expression levels were analyzed as in b, using specific antibody (Cell Signaling; 9333) . (e) Conserved miR sites in the 3 0 UTRs of IGF-1R, RSK1 and IGF-1, are shown, as predicted by TargetScan. Vertical lines indicate predicted miR-UTR pairing; miR seed sequence is in bold. Mutated 3 0 UTR sequence is shown below each UTR-miR pair, with substituted bases in italics. (f) 3 0 UTR sequences containing wild-type (wt) and mutated (mut; as shown in e) miR sites were cloned downstream of the Renilla luciferase sequence of the siCHECK dual luciferase reporter (Promega, Madison, WI, USA) and verified by sequencing. A673 cells were transiently cotransfected with the indicated reporter construct (wt or mut) and negative control or miR mimic, using the Lipofectamine 2000 reagent as in a. Renilla luciferase activity, normalized to the firefly luciferase internal control, was determined 24 h later. Data are represented as mean and standard error of the mean of two independent experiments, each performed in triplicate; activity in the control groups is set to 1 (*Po0.01).
then target multiple components of a single signaling pathway, represent a novel mechanism of oncogenesis. Such a mechanism has the potential for substantial potency. Although individual miR/target effects tend to be relatively modest, as seen in our studies, the additive effect of multiple miR/target interactions converging on a single pathway can have profound consequences. We propose that this mechanism makes an important contribution to the high activity of the IGF autocrine loop in Ewing sarcoma.
With the exception of mTOR regulation by miR-100, previously demonstrated in other contexts (Wang et al., 2008a; Nagaraja et al., 2010) , our studies identify a number of novel and important miR/target interactions. IGF-1 expression is regulated by the EWS/Fli1 oncoprotein, as previously demonstrated by both EWS/Fli1 silencing studies in Ewing sarcoma cells (Mateo-Lozano et al., 2006; Herrero-Martin et al., 2009) and EWS/Fli1 expression studies in mesenchymal progenitor cells (Cironi et al., 2008) . Analyses of the IGF-1 promoter suggest a direct transcriptional component for this regulation (Cironi et al., 2008) . Our studies uncover an additional regulatory mechanism involving miR-27a. The precise molecular mechanism by which miR-27a controls IGF-1 levels remains to be determined, as miR-27a does not appear to act through the predicted, conserved IGF-1 3 0 UTR site. Possibilities include miR regulation through other sites in the mRNA sequence, and indirect mechanisms such as miR regulation of molecules involved in controlling IGF-1 synthesis, secretion and stability. IGF-1R is also positively regulated by EWS/Fli1 at the protein level (MateoLozano et al., 2006) , and our studies identify repression of miR-100 as one mechanism of this regulation. MiR125b has multiple predicted oncogenic targets in the mitogen-activated protein kinase arm of the IGF pathway, one of which (RSK1) is demonstrated in our studies. Examination of published mRNA global profiling data moreover suggest that EWS/Fli1-repressed miRs may have a role in the regulation of other target genes in Ewing sarcoma, including GSTM4.
The phenotypic effects of most miRs show a dependence on cellular context. Our studies of a primitive malignancy of mesenchymal origin expand the scope of the contextual landscape of miR functions in cancer. Specifically, we present evidence for tumor-suppressive functions for miRs 100, 125b, 22, 221, 27a and 29a in Ewing sarcoma. Other studies of miR-100 in cancer have also found tumorsuppressive effects ( Figure 3 . One day following transfection, cells were counted, replated at 3 Â 10 4 cells/well in a 24-well plate, and cultured in growth medium with 10% serum. On the indicated days, cells were fixed with 10% formalin, washed with PBS, and stained with 0.1% crystal violet. Following extensive washing with water, cells were lysed with 10% acetic acid and the lysates were quantified spectrophotometrically (OD 570 nm ). Results are expressed as mean and standard deviation of two to three independent experiments, each performed in triplicate; the relative cell number in the control group on day 1 is set to 1. The P-values for differences between control and miR overexpressing cells on day 7 are 0.04 (miR-29a), 0.02 (miR-27a), o0.01 (miRs 100, 125b, 22 and 221). (b) Fold miR overexpression in the growth experiments in a, as determined by qRT-PCR normalized to U6 RNA. (c) A673 cells were stably transduced with control or pCDH-miR-100-Puro lentivirus as in Figure 3b . Following antibiotic selection, miR-100 expression levels were determined by qRT-PCR normalized to U6 RNA. (d, e) A total of 1 Â 10 4 control or miR-100 stable overexpressor cells were grown in 0.4% agar and growth medium with 20% serum. Colonies were stained with nitroblue tetrazolium B2-3 weeks later, and quantified using ImageJ software (rsbweb.nih.gov/ij). Results are shown as mean and standard deviation of triplicate cultures (d; P ¼ 0.01) and representative image (e). The experiment was repeated three independent times and similar results were obtained. 2010; Nagaraja et al., 2010; Sun et al., 2011) , suggesting that this may be the prevalent function of miR-100 in cancer. Similarly, miR-22 appears to have a prevalent tumor-suppressive function in cancer (Li et al., 2010; Nagaraja et al., 2010; Ting et al., 2010; Xiong et al., 2010a, b; Zhang et al., 2010c; Patel et al., 2011) , although it promotes prostate tumorigenesis (Poliseno et al., 2010) . MiR-125b has tumor-suppressive (Scott et al., 2007; Henson et al., 2009; Liang et al., 2010; Shi et al., 2010; Guan et al., 2011; Huang et al., 2011) or tumor-promoting (Xia et al., 2009; Gefen et al., 2010; Shi et al., 2011) functions, depending on context. Studies of miR-221/222 in epithelial cancers (Mercatelli et al., 2008; Garofalo et al., 2009; Wong et al., 2010) , melanoma (Felicetti et al., 2008) and glioma (Zhang et al., 2009 (Zhang et al., , 2010a have identified pro-oncogenic functions. Interestingly, however, one study of prostate cancer showed diminution of expression with tumor progression (Spahn et al., 2009) . Further, relevant to our findings in a primitive malignancy of progenitor cell origin, miR-221/222 inhibits the proliferation of embryonic stem cells (Mayoral et al., 2009) . Studies of miR-27a in carcinomas (cancers of epithelia) have identified oncogenic functions (Mertens-Talcott et al., 2007; Chintharlapalli et al., 2009; Liu et al., 2009) , although miR-27a can also enhance apoptosis (Chhabra et al., 2009) . Lastly, miR-29a also has context-dependent oncogenic (Gebeshuber et al., 2009; Han et al., 2010) or tumor-suppressive (Muniyappa et al., 2009) functions. Interestingly, the related miR-29b/c cluster is tumor suppressive in rhabdomyosarcoma (Wang et al., 2008b) , another primitive pediatric malignancy. Possible reasons for the striking context-dependent miR functions are many, including the broad repertoire of individual miR targets, miR and target relative expression levels, and coexpression of other regulators. Thus, the importance of any given miR/target interaction is likely dependent on the gene regulatory landscape of the cell. The contextual component of miR effects underscores the importance of understanding miR effects in specific cancers, especially those with unrelated histogenesis.
Our findings indicate that transcriptional repression, including possibly direct mechanisms, is at least one means by which EWS/Fli1 regulates the expression of miRs. Transcriptional repression appears to be a prevalent mechanism of target gene regulation by EWS/Fli1 in Ewing sarcoma, and there is evidence for both direct and indirect mechanisms (Jedlicka, 2010) . Direct mechanisms, in particular, are poorly understood. It will be of interest to further dissect the precise mechanisms by which EWS/Fli1 regulates miR expression at the transcriptional, as well as possibly post-transcriptional (Gregory et al., 2004) , level.
In summary, our studies identify a novel prooncogenic mechanism in Ewing sarcoma, involving targeting of the IGF signaling pathway by EWS/Fli1-regulated miRs. MiRs have been proposed, and in a number of preclinical studies demonstrated (Corsten et al., 2007; Kota et al., 2009; Cairo et al., 2010; Swarbrick et al., 2010; Trang et al., 2010; Wiggins et al., 2010; Zhou et al., 2010) , to possess therapeutic potential. Thus, although more detailed understanding of this pathway is needed, its identification presents possibilities for innovative therapeutic targeting in Ewing sarcoma and other cancers with activated IGF, as well as related receptor tyrosine kinase, signaling.
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